Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Azacitidine 142Cytarabine 109venetoclax 94fludarabine 35Daunorubicin 34Decitabine 32Idarubicin 26gilteritinib 24Cyclophosphamide 21quizartinib 15midostaurin 15Mitoxantrone 14Etoposide 14Granulocyte Colony-Stimulating Factor 12Gemtuzumab 11CPX-351 11decitabine and cedazuridine drug combination 10Drug Therapy 10cc-486 9Filgrastim 9Clofarabine 9ivosidenib 8Injections 8Dexamethasone 8pevonedistat 7fludarabine phosphate 7AP 1903 reagent 7posaconazole 6magrolimab 6glasdegib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid, Acute × Induction Chemotherapy × Clear all
NCT00943553 2015-04-13

A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Eisai Inc.

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡